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Abstract
Background/Aims: Renal involvement is common in systemic sclerosis (SSc), including 
asymptomatic reduction of glomerular filtration rate (GFR), increased renal resistance indices, 
scleroderma renal crisis (SRC) and ANCA-associated vasculitis. The aim was to evaluate type 
and evolution of renal involvement for a period of five years. Methods: 121 SSc patients (100 F, 
21 M) with mean age of 54.9 ± 13.8, disease duration of 9 ± 6 years, of which 62 had a diffused 
form and 59 limited form were enrolled. All patients were screened annually for renal function 
by laboratory examination, ultrasound and color Doppler ultrasound of renal arteries. Results: 
Over the five-year observation period, 6 SRC (3 M, 3 F) occurred, four of which required 
dialysis. One patient developed ANCA-related proliferative glomerulonephritis and the other 
one acute tubular necrosis. The remaining 113 patients had a preserved renal function (serum 
creatinine 0.75 ± 0.24 mg/dl, GFR 93.8 ± 20 ml/min, 24h proteinuria 0.20 ± 0.15 g). Doppler 
indices of intrarenal arterial stiffness increased with progression of capillaroscopic damage 
and with presence of digital ulcers. A negative correlation was observed between estimated 
GFR and pulsatile index (p<0,05, r=-0.198), resistive index(p<0,01, r=0.267), S/D ratio (p<0,01, 
r=-0.237). Conclusion: In SSc patients, renal function was normal for 4.1 years despite the 
presence of increased intrarenal arterial stiffness. SRC was observed in 4.9% of SSc patients. 
In SSc patients, a periodic follow-up based on clinical and laboratory evaluation, colorDoppler 
ultrasound  and, in some cases, renal biopsy is required  to evaluate renal involvement.
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IntroductionSystemic sclerosis (SSc) is an autoimmune disease characterized by collagen deposition 
and fibrosis of skin and internal organs [1]. The hallmarks of SSc are related to endothelial 
damage, production of autoantibodies and fibroblast dysfunction [2].
Consistently, renal involvement is frequently described in SSc, including high intrarenal 
arterial stiffness [3], isolated reduced glomerular filtration rate (GFR), reduced renal 
functional reserve, microalbuminuria and proteinuria, penicillamine-associated renal 
disease, antiphospholipid-associated nephropathy, Myeloperoxidase-Antineutrophil 
Cytoplasmic Antibody (MPO-ANCA) associated glomerulonephritis and vasculitis, to 
scleroderma renal crisis (SRC) and normotensive SRC [4].
Notably, manifestations of renal disease are observed clinically in up to 50% of SSc 
patients [5], even if autopsy studies revealed histological evidence of renal impairment in up 
to 80% of these patients [6].
In the Australia and New Zealand Dialysis and Transplant (ANZDATA) registry, 0.3% of 
the population (127 patients) developed end stage renal disease (ESRD) secondary to SSc. 
Systemic sclerosis is an uncommon cause of ESRD, which is associated with increased risks 
of both dialysis-independent renal function recovery and patient mortality compared with 
other causes of ESRD [7].
Steen et al, in 2005, studied the frequency and severity of kidney abnormalities in diffuse 
cutaneous SSc patients and they found SRC in 129/675 (19.5%) patients and reduced renal 
function or proteinuria secondary to toxicity from D-penicillamine in 173 patients (26%).
The aim of the present study was to prospectively evaluate prevalence, type and evolution 
of resistive index (RI) in patients with limited (lcSSc) and diffuse cutaneous (dcSSc) Systemic 
Sclerosis admitted to a Scleroderma Unit over a period of five years.
Materials and Methods
121 patients who met the American College 
of Rheumatology/European League Against 
Rheumatism Collaborative Initiative criteria 
for SSc admitted to the Scleroderma Unit of 
the Department of Clinical Medicine, Sapienza 
University of Rome were enrolled in the study [8]. 
Fifty-nine (48.8%) patients had lcSSc and sixty-
two (51.2%) presented dcSSc as defined by LeRoy 
et al. [9]. Table 1 shows patients’ epidemiological 
and clinical features. No patients with diabetes 
were enrolled. Patients mean follow-up was 
4.1±0.9 years, including laboratory tests and renal 
ultrasound indices. All patients were in therapy 
with nifedipine 20-30 mg day for Raynaud’s 
phenomenon. Seventy-five patients were treated 
with iloprost (0, 5-2 ng/kg/min for 8 hours for 
three days monthly) for treatment of digital ulcers 
(DUs) and Raynaud’s phenomenon. Fifty SSc 
patients received bosentan therapy (250 mg/day) 
for DUs prevention. The subjects’ written consent 
was obtained according to the Declaration of 
Helsinki and the study was approved by ethics 
committee of Sapienza University.
Table 1. Characteristics of the patients studied. 
Diffuse cutaneous SSc (dcSSc), limited cutaneous 
SSc (lcSSc), Disease Activity Index (DAI) and disease 
severity scale (DSS)
  Characteristics Value Sex (female/male) 100/21 Age (years) 54.9 ± 13.8 Disease duration (years) 9 ± 6 DAI 2.5 ± 2.1 DSS 4.9 ± 3.1 dcSSc/lcSSc 62/59 Digital ulcers history 64 (52.9)   SSc-specific autoantibodies n Anti-topoisomerase I 64 Anti-centromere 48 RNA polymerase III 3 None 6   Capillaroscopic pattern n (%) Early 29(24) Active 46 (38) Late 46 (38)   
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Clinical assessment
In all patients nailfold videocapillaroscopy (NVC) was performed (Videocapillaroscope Pinnacle 
Studio Version 8, equipped with a 500× optical probe). According to Cutolo et al., patterns identified within 
the “SSc pattern” include: early, active and late [10]. Modified Rodnan total skin score (mRSS) used to assess 
skin involvement in SSc patients [11]. Disease activity in SSc was measured using Disease Activity Index 
(DAI) [12] and disease severity was measured by Medsger Disease Severity Scale (DSS) [13].  Arterial 
hypertension was diagnosed according to ESH/ESC Guidelines for the management of arterial hypertension. 
Hypertension was defined as values >140 mmHg SBP and/or >90 mmHg DBP [14].
Laboratory parameters
Laboratory parameters included serum creatinine (sCr) (normal range: 0.5–0.9mg/dl), blood urea 
nitrogen (normal range: 10.20–49.80mg/dl), urinalysis and 24 h proteinuria. GFR was calculated with CKD-
EPI equation [15].
Renal ultrasound
Color Doppler Ultrasound of kidney (CDU) evaluated renal arteries to detect morphologic abnormalities 
or renal artery stenosis (convex 3.5-MHz probe, Toshiba Aplio Ultrasound System SSA-790, Tokyo, Japan).
A single blinded physician performed all the ultrasound examinations. The average of three 
measurements for each Doppler parameter was calculated in both kidneys at the level of arcuate and 
interlobar arteries. Peak systolic velocity (PSV), end diastolic velocity (EDV), resistive index (RI), pulsatile 
index (PI), and systolic/diastolic ratio (S/D) were measured.
RI was calculated as it follows: (peak systolic frequency shift - minimum diastolic frequency shift)/peak 
systolic frequency shift. PI was calculated as it follows: (peak systolic frequency shift)/minimum diastolic 
frequency shift)/mean frequency shift. We considered as pathologic a value of RI> 0.7 [16]. Calcium channel 
blockers and bosentan therapy was discontinued 72 hours before the CDU examination. Patients receiving 
iloprost underwent Doppler examination the day before the next infusion.
Statistical analysis
The results were expressed as mean±SD or median and range as appropriate. Commercially software 
(SPSS version 24.0) was used for statistical analysis. The coefficient of skewness and the coefficient of 
kurtosis were used to evaluate the normal distribution of data. Multiple regression analysis was applied to 
evaluate the relationship between age and Doppler indices of intrarenal stiffness and others quantitative 
variables. Pearson or Spearman correlation coefficient (r) was used to test for bivariate analysis. Group 
comparisons were made by Student’s unpaired 2-tailed t-test or the Kruskal-Wallis test, as appropriate. 
P-values <0, 05 were considered significant.
Results
Table 2 shows mean values of Doppler indices of intrarenal stiffness, sCr, CKD-EPI, 24h 
proteinuria and intimal media thickness (IMT) in SSc patients at baseline (T0) and after 
follow-up of 4.1±0.9 years (T1). No significant differences in these parameters were observed 
between T0 and T1.  Arterial hypertension was seen in 21 (17.4%) of these patients and 
their mean peak blood pressure at diagnosis was 161/98 mmHg. New hypertension was 
diagnosed only in 3 patients (2, 5%). Fifteen were in treatment with nifedipine 30 mg day 
with good control of blood pressure.  Six patients were in treatment with nifedipine 30 mg 
day plus losartan 50 mg.
Scleroderma Renal Crisis occurred in six (4.9%) patients (3 males, 3 females) of which 
five had dcSSc and one lcSSc. Three patients had anti-topoisomerase antibody, two had anti 
RNA-polymerase III antibody and one had an anti-centromere antibody. Two of them received 
10 mg of prednisone in the previous six and eight months. Four of them required dialysis 
and two of them died after nine and twelve months of SRC onset; one patient remained in 
peritoneal dialysis and recovery of dialysis-independent renal function occurred in one 
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patients after 24 months of SRC onset. The other two patients had a favorable prognosis and 
resolved the SRC within one month, following high doses of Ramipril.
MPO-ANCA associated glomerulonephritis was diagnosed in one patient who died 
3 months later, due to infectious complications; acute tubular necrosis was diagnosed in 
another patient who required dialysis only for 2 months and she remains in stage 3 chronic 
kidney disease. These patients were excluded from follow-up.
Table 3 shows the median values of Doppler indices of intrarenal stiffness, sCr, CKD-
EPI,   proteinuria 24h in six SSc patients with SRC at baseline (T0), during SRC (T1) and 
median follow-up of 60 (9-60) months (T2). The RI showed a significant increase during SRC 
and it return at normal value during the follow-up. At T1 and T2 sCr significantly (p<0.05) 
increased, conversely CKD-EPI significantly (p<0.05) reduced.
The remaining 113 patients had a preserved renal function (sCr 0.75 ± 0.24 mg/dl, CKD-
EPI 93.8 ± 20 ml/min, 24h proteinuria 0.20 ± 0.15 g). The Doppler indices of intrarenal arterial 
stiffness were: PI  1.43 ± 0.28,  RI 0.70 ± 0.05, and S/D 3.50 ± 0.76. A negative correlation 
was observed between CKD-EPI and PI (p<0, 05, r=-0.198), RI (p<0, 01, r=0.267), S/D ratio 
(p<0, 01, r=-0.237). At baseline, the mean value of PI, RI and SD significantly increased with 
progression of capillaroscopy damage (Table 4). Any difference of sCr, CKD-EPI and IMT was 
observed in three capillaroscopic groups (Table 4). At baseline the mean values of PI, RI 
and S/D were significantly higher in SSc patients with DUs than in SSc without DUs.  Any 
difference of sCr, CKD-EPI and IMT was observed in SSc patients with or without DUs (Table 
5). In multiple regression analysis, age 
showed a linear positive correlation with sCr 
(p<0, 0001, r=0, 16) and IMT (p<0, 0001, r=0, 
63) and a linear negative correlation with CKD-
EPI (p<0, 0001, r=-0, 58). Age did correlate 
with Doppler indices of intrarenal stiffness.
In SSc patients with arterial hypertension 
RI (p<0, 01, 0, 73±0, 06 vs 0, 70±0, 05) and 
S/D (p<0, 01, 3, 93±0, 93 vs 3, 41±0, 68) 
were significantly higher than in patients 
without arterial hypertension. Any significant 
difference (p>0, 05) of PI (1, 50±0, 27 vs 1, 
42±0, 28), sCr (0, 75±0, 26 vs 0, 73±0, 06) 
and CKD-EPI (86, 4±13, 8 vs 95, 4±20, 8) was 
observed between SSc patients with or without 
arterial hypertension.
None of 113 SSc patients, followed for 
a mean of 4.24±0.61 years, have developed chronic renal 
insufficiency that 
progressed to dialysis.
We did not observe 
significant differences 
renal Doppler and serological parameters 
between patients with renal complications 
and patients without 
renal complications.
Table 2. Mean values of  Doppler indices of 
intrarenal stiffness, sCr, CKD-EPI, proteinuria 24h 
and IMTin SSc patients at baseline (T0) and after 
follow-up of 4.1±0.9 years (T1). Pulsatile index 
(PI); resistive index (RI); systolic/diastolic ratio 
(S/D), serum creatinine (sCr); Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI)
 
  Variable T0 T1 p PI 1.43 ± 0.28 1.45 ± 0.30 0,78 RI 0.70 ± 0.05 0.70±0,07 0,80 S/D 3.5 ± 0.76 3,5±0,80 0,83 sCr 0.75 ± 0.24 0,78±0,26 0,79 CKD-EPI 93.8 ± 20 90±25 0,76 Proteinuria 24h  0.20±0.15 0.19±0.18 0,79 IMT 0.84± 0.18 0.83±0.21 0,77                      
 
 
Table 3. Median values and 95% LC of  Doppler indices of intrarenal stiffness, 
sCr, CKD-EPI,   proteinuria 24h  in SRC SSc patients at baseline (T0), during 
SRC (T1)  and after median follow-up of 60 (9-60) months (T2). Pulsatile index 
(PI); resistive index (RI);  systolic/diastolic ratio (S/D),  serum creatinine 
(sCr); Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
  Variable T0 T1 T2 pT0-T1 pT0-T2 PI 1.67 (1.56-1.69) 1.54 (1.48-1.84) 1.70 (1.60-1.75)  0.81 0.048 RI 0.72 (0.68-0.73) 0.78 (0.78-0.90) 0.80 (0.80-0.90) 0.02 0.18 S/D 3.62 (2.90-3.65) 4.21 (3.64-5.2) 3.50 (2.90-3.7) 0.65 0.1 sCr 0.8 (0.8-0.9) 3.05 (1.20-4.05) 2.85 (0.90-4) 0.02 0.026 CKD-EPI 90 (88-109) 18 (15-49) 18 (15-69)  0.013 0.041 Proteinuria 24h  0.17 (0.14-0.19) 0.9 (0.5-1.3) 0.85 (0.12-1.05) 0.02 0.3                   
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Discussion
In our Scleroderma Unit, we have evaluated the clinical setting and long-term outcome 
of kidney disease secondary to SSc. According to studies published in the past 20 years, SRC 
in the United States has been reported in 10% of dcSSc patients and 2% of lcSSc patients 
[17]. Until a few years ago, SRC was the most severe complication and frequent cause of 
death reported in SSc [18]. Large studies have identified some factors that can be helpful in 
the evaluation of patients at high risk for SRC. Among these factors, some of them cannot be 
modified, such as autoantibody profile positive for anti-RNA polymerase III, arthritis, skin 
involvement and tendon friction rubs. The only modifiable factor is corticosteroid exposure 
≥15 mg per day in the preceding 6 months [19]. Although the reasons for this effect are not 
yet well understood, it is possible that high doses of corticosteroids can promote endothelial 
dysfunction and inhibit prostacyclin production, in turn increasing ACE activity [18]. In our 
study only six patients (4.9%), five with diffuse SSc and one with limited SSc, developed 
SRC. Three patients had anti-topoisomerase antibody, two had anti RNA-polymerase III and 
only one had an anti-centromere antibody. Four of these six patients required hemodialysis 
and in two of them renal biopsy was performed because rapidly progressive oliguric renal 
failure since MPO-ANCA glomerulonephritis should be considered. One case of MPO-ANCA 
glomerulonephritis was diagnosed with renal biopsy while we have not registered associated 
APS nephropathy. In our cohort, one patient developed tubular acute necrosis, probably 
due to antibiotics (cephalosporin) toxicity. Several drugs hold the potential to cause renal 
damage, especially non-steroidal anti-inflammatory drugs able to induce tubulointerstitial 
nephritis. These manifestations are not related to SSc, and renal biopsy is required for 
accurate differential diagnosis. In the past, D-Penicillamine was administered to treat SSc, 
which was promoting renal complications like membranous glomerulopathy, proliferative 
crescentic glomerulonephritis and Goodpasture’s Syndrome [4].
In SSc patients, renal function is normal despite the presence of increased intrarenal 
arterial stiffness. Renal function is preserved also in SSc patients with long disease duration. 
Age represents an independent risk factor for GFR decline [3]. Glomerular filtrate rate 
depends closely on the age and GFR remains constant on the mean values of 140 ml/
min/1.73 m2 until the fourth decade then it declines by about 8 ml/min/1.73 m2 per further 
decade [20]. Despite preserved renal function, in SSc patients Doppler indices of intrarenal 
arterial stiffness are higher than general population [3]. In our study, in SSc patients with 
arterial hypertension RI and SD were significantly higher than in patients without arterial 
Table 5. Mean values and SD of Doppler 
indices of intrarenal stiffness, sCrand  CKD-
EPI in SSc patients with and without digital 
ulcers (DUs). Pulsatile index (PI); resistive 
index (RI);  systolic/diastolic ratio (S/D); 
serum creatinine (sCr); Chronic Kidney 
Disease Epidemiology Collaboration (CKD-
EPI); Intimal media thickness (IMT)
    Variable SSc patients with DUs SSc patients without DUs p PI 1,53±0,30 1,32±0,21 <0,0001 RI 0,72±0,04 0,68±0,04 <0,0001 S/D 3,77±0,82 3,20±0,54 <0,0001 sCr 0,76±0,30 0,74±0,15 0,93 CKD-EPI 93,5±23,1 94,1±16 0,83 IMT 0,87±0,18 0,81±0,17 0,058  
 
Table 4. Mean values and SD of Doppler 
indices of intrarenal stiffness, sCrand 
CKD-EPI in three capillaroscopic groups. 
Pulsatile index (PI); resistive index (RI); 
systolic/diastolic ratio (S/D); serum 
creatinine (sCr); Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI); 
Intimal media thickness (IMT)
   Variable Early Active Late p PI 1,32±0,26 1,42±0,23 1,52±0,32 0,016 RI 0,67±0,05 0,70±0,05 0,72±0,06 <0,0001 S/D 3,12±0,69 3,50±0,64 3,75±0,81 0,013 sCr 0,77±0,17 0,73±0,23 0,74±0,30 0,30 CKD-EPI 93,3±18,9 92,9±20 95,1±21 0,59 IMT 0,79±0,14 0,85±0,19 0,86±0,18 0,22                 
 
 
 
 
 
 
 Kidney Blood Press Res 2018;43:682-689
DOI: 10.1159/000489740
Published online: 16 May, 2018
© 2018 The Author(s). Published by S. Karger AG, Basel
www.karger.com/kbr 687
Rosato et al.: Kidney and Systemic Sclerosis
hypertension. It is well known that hypertension is among major parameters that influence 
intrarenal resistance [16].
In this study we observed a negative correlation between Doppler indices of intrarenal 
arterial stiffness and estimated GFR evaluated by CKD-EPI. The Doppler indices of intrarenal 
arterial stiffness increased with progression of capillaroscopic damage and they are higher 
in SSc patients with DUs than in SSc patients without DUs. Subclinical and asymptomatic 
renal impairment is common in SSc and correlates with microvascular manifestations and 
prognosis. In previous studies, we have demonstrated that intrarenal arterial stiffness is 
increased significantly in SSc patients than healthy control and correlate with capillaroscopic 
damage [3]. Renal hemodynamic parameters negatively correlate with estimated and 
measured GFR and they are a marker of new DUs occurrence [21, 22]. In this study we did 
not observe significant differences of CKD-EPI between SSc patients with and without DUs. 
This difference compared to previous studies is due to the presence of different criteria 
of inclusion and exclusion (e.g. arterial hypertension). Many patients without DUs had 
arterial hypertension. Arterial hypertension is a risk factor for the reduction of GFR. In SSc 
patients, intrarenal arterial stiffness is considered an early marker in course of SRC [23] and 
cardiorenal syndrome [24]. Recently, Rosato et al. have demonstrated that RI are increased in 
SSc patients with anti-RNA polymerase III antibodies [25]. Thus, Doppler indices are reliable 
markers both in asymptomatic and in high risk renal vascular complications.
Based on these findings, we suggest that all patients with SSc should be carefully 
evaluated for symptomatic and asymptomatic renal involvement. Asymptomatic renal 
vasculopathy is frequently present but it does not seem to be associated with poorer 
outcome. Scleroderma Renal Crisis remains a severe manifestation of SSc despite treatment 
with high dose of angiotensin-converting enzyme inhibitor and dialysis.
Conclusion
In our cohort of SSc patients, renal function, evaluated by CKD-EPI, remained normal for 
4.1 years despite the presence of increased intrarenal arterial stiffness. In addition, 4.9% of 
SSc patients developed SRC as main renal vascular complication. We can suggest that in SSc 
patients Doppler indices of intrarenal arterial stiffness should be performed in association 
with others markers of laboratory (sCr, urinalysis, estimated GFR, 24 h proteinuria) to evaluate 
vascular renal involvement. A renal biopsy should be strongly recommended to differentiate 
SRC from rapidly progressive glomerulonephritis such as MPO- ANCA positive associated or 
crescentic glomerulonephritis, because treatment regimens, patients’ management as well 
as clinical outcomes are significantly different.
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